Interestingly, they showed that trastuzumab-IR800 had accumulation in both HER2 positive and HER2 negative xenografts, while 11A4-IR800 had accumulation only in HER2 positive breast cancer xenografts and no accumulation in HER2 negative tumors. This evidence concerns the gene ERBB2 and breast carcinoma.